352 related articles for article (PubMed ID: 8233444)
1. [The place of insulin-like growth factor I in the diagnosis of acromegaly].
Dohán O; Góth M; Szabolcs I; Kovács L; Kovács Z; Szilágyi G
Orv Hetil; 1993 Oct; 134(42):2301-3. PubMed ID: 8233444
[TBL] [Abstract][Full Text] [Related]
2. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis.
van der Lely AJ; de Herder WW; Janssen JA; Lamberts SW
J Endocrinol; 1997 Oct; 155 Suppl 1():S9-13; discussion S15-6. PubMed ID: 9389990
[TBL] [Abstract][Full Text] [Related]
4. Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults.
Thissen JP; Ketelslegers JM; Maiter D
Growth Regul; 1996 Dec; 6(4):222-9. PubMed ID: 8971551
[TBL] [Abstract][Full Text] [Related]
5. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly.
Wass JA
J Endocrinol; 1997 Oct; 155 Suppl 1():S17-9; discussion S21. PubMed ID: 9389991
[TBL] [Abstract][Full Text] [Related]
7. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.
Taboada GF; Correa LL; de Oliveira Machado E; van Haute FR; Casini AF; Balarini GA; Neto LV; Calixto L; Calixto C; Gadelha MR
Growth Horm IGF Res; 2007 Feb; 17(1):77-81. PubMed ID: 17314058
[TBL] [Abstract][Full Text] [Related]
8. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
9. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
10. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
11. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
[TBL] [Abstract][Full Text] [Related]
12. Detection of colorectal lesions by using autofluorescence colonoscopy in acromegalics and their relation to serum growth hormone and insulin-like growth factor-1 levels.
Matyja V; Kos-Kudla B; Foltyn W; Strzelczyk J; Latos W; Marek B; Kajdaniuk D; Karpe J; Ostrowska Z; Sieron-Stoltny K; Sieron A
Neuro Endocrinol Lett; 2006 Oct; 27(5):639-43. PubMed ID: 17159821
[TBL] [Abstract][Full Text] [Related]
13. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population.
Granada ML; Ulied A; Casanueva FF; Pico A; Lucas T; Torres E; Sanmartí A
Clin Endocrinol (Oxf); 2008 Jun; 68(6):942-50. PubMed ID: 17980002
[TBL] [Abstract][Full Text] [Related]
14. Serum adiponectin levels in adult growth hormone deficiency and acromegaly.
Fukuda I; Hizuka N; Ishikawa Y; Itoh E; Yasumoto K; Murakami Y; Sata A; Tsukada J; Kurimoto M; Okubo Y; Takano K
Growth Horm IGF Res; 2004 Dec; 14(6):449-54. PubMed ID: 15519253
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
Wiesli P; Zwimpfer C; Zapf J; Schmid C
Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
[TBL] [Abstract][Full Text] [Related]
16. Perioperative plasma active and total ghrelin levels are reduced in acromegaly when compared with in nonfunctioning pituitary tumours even after normalization of serum GH.
Kawamata T; Inui A; Hosoda H; Kangawa K; Hori T
Clin Endocrinol (Oxf); 2007 Jul; 67(1):140-4. PubMed ID: 17466003
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
18. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
19. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
Ho KY; Weissberger AJ
Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
[TBL] [Abstract][Full Text] [Related]
20. [Study on the activity of acromegaly: evaluation of IGF-I].
Larrañaga J; Carbó E; Horcajada C; Herrera Pombo JL
Rev Clin Esp; 1991 Feb; 188(3):131-5. PubMed ID: 1780511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
